Oneview Healthcare (ASX: ONE) reported a 9-percentage-point expansion in gross margin to 70% for the first half of 2026, alongside a 13% increase in recurring revenue to €4.3 million, as the company advanced its integration with Epic Systems in the U.S. healthcare market.
Total revenue declined 14% year-over-year to €5.5 million, reflecting a 54% drop in non-recurring revenue to €1.2 million. Gross profit remained flat at €3.8 million, while operating EBITDA loss improved 11% to €4.0 million. Operating cash outflow narrowed 15% to €4.1 million, a 22% improvement from H1 2024 levels. The company’s cash position stood at €7.2 million as of June 30, with pro forma cash rising to €11.4 million following a A$19 million institutional placement finalized in two tranches—€12 million in March and €7 million subsequently.
Recurring revenue accounted for 79% of total revenue, up from 60% a year earlier, supported by the deployment of 693 new endpoints in H1 2026, which generated 59% higher average recurring revenue per endpoint than decommissioned units. Live endpoints totaled 15,092 as of June 30, though Oneview noted an unforeseen delay to approximately 1,000 endpoints at Children’s Hospital Ireland due to construction timeline extensions. Headcount averaged 90 employees, down from 98 in H2 2024.
The company highlighted progress in its U.S. commercial pipeline, with 131 open opportunities under the Baxter funnel representing 36,375 licensed beds, and 16 active Bedside Hub opportunities covering 19,860 beds—nine of which were reactivated post-Epic certification in May 2026. A 15-bed pilot is scheduled to begin in September across three hospitals within a top-20 U.S. health system. Oneview also secured a group purchasing organization agreement covering more than 85 hospitals and 15,000 beds, while leveraging Epic’s dominance in the U.S. acute care market, where 43.7% of hospitals—representing 56.9% of beds—use the platform as of 2025.
Operational efficiency gains were underscored by a 1.7x increase in feature development speed and a fivefold acceleration in bug root-cause investigation, with approximately 85% of code now generated by AI agents under human supervision. Development processes are aligned with ISO 42001 standards, and the company is conducting a SOC 2 Type II gap assessment. Oneview’s stock rose 6.25% to $0.17 following the presentation, within a 52-week range of $0.13 to $0.41.
